{"id":"pdl1","name":"PD-L1","symbol":"CD274","route":"/targets/pdl1/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17635","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000120217","uniprot":"https://www.uniprot.org/uniprotkb/Q9NZQ7/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q9NZQ7","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL3580522","open-targets":"https://platform.opentargets.org/target/ENSG00000120217","civic":"https://civicdb.org/genes/29126/summary","oncokb":"https://www.oncokb.org/gene/CD274","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CD274","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=CD274","depmap":"https://depmap.org/portal/gene/CD274?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000120217-CD274","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/29126","omim":"https://www.omim.org/entry/605402"}],"products":[{"id":"acasunlimab","name":"Acasunlimab","status":"phase-3","modality":"bispecific antibody","route":"/drugs/acasunlimab/"},{"id":"adebrelimab","name":"Adebrelimab","status":"approved","modality":"Monoclonal antibody (anti-PD-L1, humanised IgG4)","route":"/drugs/adebrelimab/"},{"id":"atezolizumab","name":"Atezolizumab","status":"approved","modality":"Monoclonal antibody (anti-PD-L1)","route":"/drugs/atezolizumab/"},{"id":"avelumab","name":"Avelumab","status":"approved","modality":"Monoclonal antibody (anti-PD-L1)","route":"/drugs/avelumab/"},{"id":"benmelstobart","name":"Benmelstobart","status":"approved","modality":"Anti-PD-L1 monoclonal antibody","route":"/drugs/benmelstobart/"},{"id":"cosibelimab","name":"Cosibelimab","status":"approved","modality":"Anti-PD-L1 monoclonal antibody (IgG1, ADCC-competent)","route":"/drugs/cosibelimab/"},{"id":"durvalumab","name":"Durvalumab","status":"approved","modality":"Monoclonal antibody (anti-PD-L1)","route":"/drugs/durvalumab/"},{"id":"envafolimab","name":"Envafolimab","status":"approved","modality":"Single-domain antibody (anti-PD-L1, subcutaneous)","route":"/drugs/envafolimab/"},{"id":"hb0036","name":"HB0036","status":"phase-2","modality":"bifunctional antibody (anti-PD-L1/anti-TIGIT, per the sponsor's description; form not stated in the registry record)","route":"/drugs/hb0036/"},{"id":"hlx43","name":"HLX43","status":"phase-3","modality":"ADC","route":"/drugs/hlx43/"},{"id":"io102-io103","name":"IO102-IO103","status":"phase-3","modality":"peptide (immunotherapeutic vaccine)","route":"/drugs/io102-io103/"},{"id":"iparomlimab-tuvonralimab","name":"Iparomlimab and tuvonralimab","status":"approved","modality":"Bifunctional antibody mixture: anti-PD-1 and anti-CTLA-4","route":"/drugs/iparomlimab-tuvonralimab/"},{"id":"dako-pd-l1-22c3-pharmdx","name":"PD-L1 IHC 22C3 pharmDx","status":"approved","modality":"PD-L1 immunohistochemistry companion diagnostic assay","route":"/drugs/dako-pd-l1-22c3-pharmdx/"},{"id":"pf-08046054","name":"PF-08046054","status":"phase-3","modality":"ADC","route":"/drugs/pf-08046054/"},{"id":"pm8002","name":"PM8002","status":"phase-3","modality":"bispecific antibody","route":"/drugs/pm8002/"},{"id":"retlirafusp-alfa","name":"Retlirafusp alfa","status":"phase-3","modality":"Bifunctional fusion protein (anti-PD-L1 antibody fused to a TGF-beta receptor II trap), intravenous","route":"/drugs/retlirafusp-alfa/"},{"id":"sasanlimab","name":"Sasanlimab","status":"phase-3","modality":"monoclonal antibody","route":"/drugs/sasanlimab/"},{"id":"socazolimab","name":"Socazolimab","status":"phase-3","modality":"Anti-PD-L1 monoclonal antibody, intravenous","route":"/drugs/socazolimab/"},{"id":"ssgj-706","name":"SSGJ-706","status":"phase-2","modality":"bispecific antibody","route":"/drugs/ssgj-706/"},{"id":"sugemalimab","name":"Sugemalimab","status":"approved","modality":"Monoclonal antibody (anti-PD-L1, fully human IgG4)","route":"/drugs/sugemalimab/"},{"id":"t3011","name":"T3011","status":"phase-2","modality":"oncolytic virus (intratumoral oncolytic HSV-1, per the sponsor's pipeline page; registered as a drug on ClinicalTrials.gov)","route":"/drugs/t3011/"},{"id":"tiragolumab","name":"Tiragolumab","status":"negative","modality":"Monoclonal antibody (anti-TIGIT)","route":"/drugs/tiragolumab/"},{"id":"tqb2450","name":"TQB2450","status":"phase-3","modality":"monoclonal antibody","route":"/drugs/tqb2450/"},{"id":"ventana-pd-l1-sp142","name":"VENTANA PD-L1 (SP142) Assay","status":"approved","modality":"PD-L1 immunohistochemistry companion diagnostic assay","route":"/drugs/ventana-pd-l1-sp142/"},{"id":"ventana-pd-l1-sp263","name":"VENTANA PD-L1 (SP263) Assay","status":"approved","modality":"PD-L1 immunohistochemistry companion diagnostic assay","route":"/drugs/ventana-pd-l1-sp263/"}],"trials":[{"id":"dellphi-305","name":"DeLLphi-305","nct":"NCT06211036","phase":"3","status":"positive"},{"id":"dream3r","name":"DREAM3R","nct":"NCT04334759","phase":"3","status":"negative"},{"id":"emerald-3","name":"EMERALD-3","nct":"NCT05301842","phase":"3","status":"positive"},{"id":"gepardouze","name":"GeparDouze / NSABP B-59","nct":"NCT03281954","phase":"3","status":"negative"},{"id":"nct03706690","name":"A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients","nct":"NCT03706690","phase":"3","status":"active"},{"id":"impassion030","name":"ALEXANDRA / IMpassion030","nct":"NCT03498716","phase":"3","status":"negative"},{"id":"atomic","name":"ATOMIC (Alliance A021502)","nct":"NCT02912559","phase":"3","status":"positive"},{"id":"imforte","name":"IMforte","nct":"NCT05091567","phase":"3","status":"positive"},{"id":"imvigor011","name":"IMvigor011","nct":"NCT04660344","phase":"3","status":"positive"},{"id":"keynote-b96","name":"KEYNOTE-B96 / ENGOT-ov65","nct":"NCT05116189","phase":"3","status":"positive"},{"id":"matterhorn","name":"MATTERHORN","nct":"NCT04592913","phase":"3","status":"positive"},{"id":"nct05224141","name":"Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)","nct":"NCT05224141","phase":"3","status":"active"},{"id":"potomac","name":"POTOMAC","nct":"NCT03528694","phase":"3","status":"positive"},{"id":"nct04665856","name":"Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer","nct":"NCT04665856","phase":"3","status":"completed"},{"id":"nct04446117","name":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC","nct":"NCT04446117","phase":"3","status":"active"},{"id":"nct03755791","name":"Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Rece","nct":"NCT03755791","phase":"3","status":"active"},{"id":"a-brave","name":"A-BRAVE","nct":"NCT02926196","phase":"3","status":"mixed"},{"id":"adriatic","name":"ADRIATIC","nct":"NCT03703297","phase":"3","status":"positive"},{"id":"beat-meso","name":"BEAT-meso (ETOP 13-18)","nct":"NCT03762018","phase":"3","status":"mixed"},{"id":"emerald-1","name":"EMERALD-1","nct":"NCT03778957","phase":"3","status":"mixed"},{"id":"mermaid-2","name":"MERMAID-2","nct":"NCT04642469","phase":"3","status":"completed"},{"id":"niagara","name":"NIAGARA","nct":"NCT03732677","phase":"3","status":"positive"},{"id":"pacific-2","name":"PACIFIC-2","nct":"NCT03519971","phase":"3","status":"negative"},{"id":"nct03800134","name":"A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer","nct":"NCT03800134","phase":"3","status":"active"},{"id":"beatcc","name":"BEATcc / ENGOT-Cx10 / GOG-3030","nct":"NCT03556839","phase":"3","status":"positive"},{"id":"calla","name":"CALLA","nct":"NCT03830866","phase":"3","status":"negative"},{"id":"contact-03","name":"CONTACT-03","nct":"NCT04338269","phase":"3","status":"negative"},{"id":"duo-e","name":"DUO-E / GOG-3041 / ENGOT-EN10","nct":"NCT04269200","phase":"3","status":"positive"},{"id":"duo-o","name":"DUO-O / ENGOT-ov46","nct":"NCT03737643","phase":"3","status":"mixed"},{"id":"imbrave050","name":"IMbrave050","nct":"NCT04102098","phase":"3","status":"negative"},{"id":"nct03003962","name":"Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)","nct":"NCT03003962","phase":"3","status":"active"},{"id":"capstone-1","name":"CAPSTONE-1","nct":"NCT03711305","phase":"3","status":"positive"},{"id":"gemstone-301","name":"GEMSTONE-301","nct":"NCT03728556","phase":"3","status":"positive"},{"id":"gemstone-302","name":"GEMSTONE-302","nct":"NCT03789604","phase":"3","status":"positive"},{"id":"himalaya","name":"HIMALAYA","nct":"NCT03298451","phase":"3","status":"positive"},{"id":"imbassador250","name":"IMbassador250","nct":"NCT03016312","phase":"3","status":"negative"},{"id":"neotrip","name":"NeoTRIP (NeoTRIPaPDL1)","nct":"NCT02620280","phase":"3","status":"negative"},{"id":"nct03164616","name":"Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).","nct":"NCT03164616","phase":"3","status":"active"},{"id":"nct02542293","name":"Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)","nct":"NCT02542293","phase":"3","status":"active"},{"id":"topaz-1","name":"TOPAZ-1","nct":"NCT03875235","phase":"3","status":"positive"},{"id":"empower-lung-1","name":"EMPOWER-Lung 1","nct":"NCT03088540","phase":"3","status":"positive"},{"id":"nct02516241","name":"Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer","nct":"NCT02516241","phase":"3","status":"active"},{"id":"nct02486718","name":"Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [","nct":"NCT02486718","phase":"3","status":"positive"},{"id":"checkmate-649","name":"CheckMate 649","nct":"NCT02872116","phase":"3","status":"positive"},{"id":"imbrave150","name":"IMbrave150","nct":"NCT03434379","phase":"3","status":"positive"},{"id":"impassion031","name":"IMpassion031","nct":"NCT03197935","phase":"3","status":"positive"},{"id":"impassion131","name":"IMpassion131","nct":"NCT03125902","phase":"3","status":"negative"},{"id":"impower110","name":"IMpower110","nct":"NCT02409342","phase":"3","status":"positive"},{"id":"imspire150","name":"IMspire150","nct":"NCT02908672","phase":"3","status":"positive"},{"id":"javelin-bladder-100","name":"JAVELIN Bladder 100","nct":"NCT02603432","phase":"3","status":"positive"},{"id":"javelin-hn-100","name":"JAVELIN Head and Neck 100","nct":"NCT02952586","phase":"3","status":"negative"},{"id":"caspian","name":"CASPIAN","nct":"NCT03043872","phase":"3","status":"positive"},{"id":"imblaze370","name":"IMblaze370","nct":"NCT02788279","phase":"3","status":"negative"},{"id":"keynote-042","name":"KEYNOTE-042","nct":"NCT02220894","phase":"3","status":"positive"},{"id":"keynote-048","name":"KEYNOTE-048","nct":"NCT02358031","phase":"3","status":"positive"},{"id":"nct02453282","name":"Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)","nct":"NCT02453282","phase":"3","status":"active"},{"id":"impassion130","name":"IMpassion130","nct":"NCT02425891","phase":"3","status":"mixed"},{"id":"impower133","name":"IMpower133","nct":"NCT02763579","phase":"3","status":"positive"},{"id":"impower150","name":"IMpower150","nct":"NCT02366143","phase":"3","status":"positive"},{"id":"checkmate-026","name":"CheckMate 026","nct":"NCT02041533","phase":"3","status":"negative"},{"id":"pacific","name":"PACIFIC","nct":"NCT02125461","phase":"3","status":"positive"},{"id":"keynote-024-189","name":"KEYNOTE-024 & KEYNOTE-189","nct":"NCT02142738","phase":"3","status":"positive"},{"id":"oak","name":"OAK","nct":"NCT02008227","phase":"3","status":"positive"},{"id":"checkmate-017","name":"CheckMate 017","nct":"NCT01642004","phase":"3","status":"positive"},{"id":"checkmate-057","name":"CheckMate 057","nct":"NCT01673867","phase":"3","status":"positive"},{"id":"nct06469879","name":"A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients","nct":"NCT06469879","phase":"3","status":"planned"},{"id":"nct07111832","name":"A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer","nct":"NCT07111832","phase":"3","status":"recruiting"},{"id":"nct07168200","name":"A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the","nct":"NCT07168200","phase":"3","status":"recruiting"},{"id":"nct06112379","name":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","nct":"NCT06112379","phase":"3","status":"active"},{"id":"nct07005128","name":"A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small","nct":"NCT07005128","phase":"3","status":"active"},{"id":"nct05904886","name":"A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocell","nct":"NCT05904886","phase":"3","status":"active"},{"id":"nct07822542","name":"A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Pat","nct":"NCT07822542","phase":"3","status":"planned"},{"id":"nct04873362","name":"A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy","nct":"NCT04873362","phase":"3","status":"active"},{"id":"nct05170204","name":"A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small C","nct":"NCT05170204","phase":"3","status":"active"},{"id":"nct03148418","name":"A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)","nct":"NCT03148418","phase":"3","status":"active"},{"id":"nct06617416","name":"A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC","nct":"NCT06617416","phase":"3","status":"recruiting"},{"id":"nct05047250","name":"A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer","nct":"NCT05047250","phase":"3","status":"active"},{"id":"nct06789796","name":"a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy","nct":"NCT06789796","phase":"3","status":"planned"},{"id":"nct07221253","name":"A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)","nct":"NCT07221253","phase":"3","status":"recruiting"},{"id":"nct04165317","name":"A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer","nct":"NCT04165317","phase":"3","status":"active"},{"id":"nct07672223","name":"A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)","nct":"NCT07672223","phase":"3","status":"planned"},{"id":"nct04712643","name":"A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma","nct":"NCT04712643","phase":"3","status":"active"},{"id":"nct04523272","name":"A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer","nct":"NCT04523272","phase":"3","status":"active"},{"id":"nct07679360","name":"A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer","nct":"NCT07679360","phase":"3","status":"recruiting"},{"id":"nct07361497","name":"A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell","nct":"NCT07361497","phase":"3","status":"recruiting"},{"id":"nct07361510","name":"A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and P","nct":"NCT07361510","phase":"3","status":"recruiting"},{"id":"nct06746116","name":"A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment","nct":"NCT06746116","phase":"3","status":"active"},{"id":"nsclc-4","name":"A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)","nct":"NCT07144280","phase":"3","status":"recruiting"},{"id":"nct07393542","name":"A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma","nct":"NCT07393542","phase":"3","status":"recruiting"},{"id":"nct04950322","name":"A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer","nct":"NCT04950322","phase":"3","status":"active"},{"id":"nct06672133","name":"Adebrelimab Combined with Chemotherapy and Thoracic Radiotherapy for First-line Treatment of ES-SCLC","nct":"NCT06672133","phase":"3","status":"planned"},{"id":"nct06591520","name":"AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer","nct":"NCT06591520","phase":"3","status":"active"},{"id":"nct05112965","name":"An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)","nct":"NCT05112965","phase":"3","status":"active"},{"id":"nct07720284","name":"An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC","nct":"NCT07720284","phase":"3","status":"recruiting"},{"id":"nct03847428","name":"Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment","nct":"NCT03847428","phase":"3","status":"active"},{"id":"nct03977194","name":"Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy","nct":"NCT03977194","phase":"3","status":"active"},{"id":"nct03815643","name":"Avelumab Program Rollover Study","nct":"NCT03815643","phase":"3","status":"active"},{"id":"nct05943106","name":"BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants","nct":"NCT05943106","phase":"3","status":"active"},{"id":"nct07195695","name":"Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutati","nct":"NCT07195695","phase":"3","status":"recruiting"},{"id":"nct07625644","name":"BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)","nct":"NCT07625644","phase":"3","status":"recruiting"},{"id":"nct05317858","name":"Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets","nct":"NCT05317858","phase":"3","status":"recruiting"},{"id":"nct07522151","name":"Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer","nct":"NCT07522151","phase":"3","status":"recruiting"},{"id":"nct04516681","name":"Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer","nct":"NCT04516681","phase":"3","status":"recruiting"},{"id":"nct06632327","name":"Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer","nct":"NCT06632327","phase":"3","status":"active"},{"id":"nct01993810","name":"Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer","nct":"NCT01993810","phase":"3","status":"active"},{"id":"nct05059522","name":"Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing","nct":"NCT05059522","phase":"3","status":"active"},{"id":"nct07472517","name":"DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment","nct":"NCT07472517","phase":"3","status":"recruiting"},{"id":"nct06992609","name":"Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.","nct":"NCT06992609","phase":"3","status":"active"},{"id":"nct04597671","name":"Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28)","nct":"NCT04597671","phase":"3","status":"active"},{"id":"nct05883644","name":"Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)","nct":"NCT05883644","phase":"3","status":"active"},{"id":"nct05557838","name":"Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC","nct":"NCT05557838","phase":"3","status":"active"},{"id":"nct05771480","name":"Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)","nct":"NCT05771480","phase":"3","status":"active"},{"id":"nct03833154","name":"Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation","nct":"NCT03833154","phase":"3","status":"active"},{"id":"nct04465968","name":"Efficacy and Safety of CRT, Durvalumab and Surgery for SST","nct":"NCT04465968","phase":"3","status":"planned"},{"id":"nct05482516","name":"Evaluating Novel Therapies in ctDNA Positive GI Cancers","nct":"NCT05482516","phase":"3","status":"recruiting"},{"id":"nct06733038","name":"FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.","nct":"NCT06733038","phase":"3","status":"recruiting"},{"id":"nct07710885","name":"Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer","nct":"NCT07710885","phase":"3","status":"recruiting"},{"id":"nct06498635","name":"Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial","nct":"NCT06498635","phase":"3","status":"recruiting"},{"id":"nct05155254","name":"IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)","nct":"NCT05155254","phase":"3","status":"active"},{"id":"nct07620574","name":"Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study","nct":"NCT07620574","phase":"3","status":"recruiting"},{"id":"mermaid-1","name":"MERMAID-1","nct":"NCT04385368","phase":"3","status":"completed"},{"id":"nct06960577","name":"Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)","nct":"NCT06960577","phase":"3","status":"recruiting"},{"id":"nct04585490","name":"Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC","nct":"NCT04585490","phase":"3","status":"recruiting"},{"id":"nct06467357","name":"Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer","nct":"NCT06467357","phase":"3","status":"recruiting"},{"id":"nct06123754","name":"Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC","nct":"NCT06123754","phase":"3","status":"recruiting"},{"id":"nct06921785","name":"Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma","nct":"NCT06921785","phase":"3","status":"recruiting"},{"id":"nct06459687","name":"Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer","nct":"NCT06459687","phase":"3","status":"recruiting"},{"id":"nct05687266","name":"Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations","nct":"NCT05687266","phase":"3","status":"active"},{"id":"nct06616532","name":"PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer","nct":"NCT06616532","phase":"3","status":"active"},{"id":"nct06419621","name":"PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC","nct":"NCT06419621","phase":"3","status":"active"},{"id":"nct05752136","name":"Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma","nct":"NCT05752136","phase":"3","status":"recruiting"},{"id":"nct03478488","name":"Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC","nct":"NCT03478488","phase":"3","status":"active"},{"id":"mcc-rational-treatment","name":"Rational treatment selection for Merkel cell carcinoma","nct":"ISRCTN16290169","phase":"3","status":"completed"},{"id":"nct07173751","name":"ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer","nct":"NCT07173751","phase":"3","status":"recruiting"},{"id":"nct06712355","name":"Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer","nct":"NCT06712355","phase":"3","status":"recruiting"},{"id":"nct05043090","name":"Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC","nct":"NCT05043090","phase":"3","status":"active"},{"id":"nct03682068","name":"Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer","nct":"NCT03682068","phase":"3","status":"active"},{"id":"nct04550260","name":"Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC","nct":"NCT04550260","phase":"3","status":"active"},{"id":"nct06890598","name":"Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer","nct":"NCT06890598","phase":"3","status":"recruiting"},{"id":"nct04786964","name":"Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC","nct":"NCT04786964","phase":"3"},{"id":"nct05425940","name":"Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer","nct":"NCT05425940","phase":"3","status":"active"},{"id":"nct07637513","name":"Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer","nct":"NCT07637513","phase":"3","status":"planned"},{"id":"nct06908993","name":"Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated","nct":"NCT06908993","phase":"3","status":"recruiting"},{"id":"nct03811002","name":"Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lun","nct":"NCT03811002","phase":"3","status":"active"},{"id":"nct04092283","name":"Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Anti","nct":"NCT04092283","phase":"3","status":"active"},{"id":"nct02997228","name":"Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study","nct":"NCT02997228","phase":"3","status":"active"},{"id":"nct06732401","name":"Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer","nct":"NCT06732401","phase":"3","status":"active"},{"id":"nct05624996","name":"Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer","nct":"NCT05624996","phase":"3","status":"recruiting"},{"id":"nct04214262","name":"Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer","nct":"NCT04214262","phase":"3","status":"active"},{"id":"nct07388524","name":"Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial","nct":"NCT07388524","phase":"3","status":"recruiting"},{"id":"nct05468489","name":"To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC","nct":"NCT05468489","phase":"3","status":"active"},{"id":"nct04960709","name":"Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin","nct":"NCT04960709","phase":"3","status":"active"},{"id":"nct06635824","name":"Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)","nct":"NCT06635824","phase":"3","status":"active"},{"id":"tropion-breast03","name":"TROPION-Breast03","nct":"NCT05629585","phase":"3","status":"active"},{"id":"tropion-breast05","name":"TROPION-Breast05","nct":"NCT06103864","phase":"3","status":"recruiting"},{"id":"nct06955325","name":"Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations","nct":"NCT06955325","phase":"3","status":"planned"},{"id":"keynote-010","name":"KEYNOTE-010","nct":"NCT01905657","phase":"2/3","status":"positive"},{"id":"nct06959693","name":"A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Col","nct":"NCT06959693","phase":"2/3","status":"planned"},{"id":"nct07459751","name":"A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer","nct":"NCT07459751","phase":"2/3","status":"recruiting"},{"id":"nct06335355","name":"A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients","nct":"NCT06335355","phase":"2/3","status":"planned"},{"id":"nct03178552","name":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","nct":"NCT03178552","phase":"2/3","status":"active"},{"id":"nct07221357","name":"A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Parti","nct":"NCT07221357","phase":"2/3","status":"recruiting"},{"id":"nct07221149","name":"A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)","nct":"NCT07221149","phase":"2/3","status":"recruiting"},{"id":"nct06879145","name":"Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)","nct":"NCT06879145","phase":"2/3","status":"recruiting"},{"id":"nct05770102","name":"DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Mi","nct":"NCT05770102","phase":"2/3","status":"recruiting"},{"id":"ea2197-ivonescimab","name":"EA2197 ivonescimab: ivonescimab with gemcitabine and cisplatin versus standard chemo-immunotherapy in advanced biliary tract cancer","nct":"NCT07765433","phase":"2/3","status":"planned"},{"id":"nct07636226","name":"QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer","nct":"NCT07636226","phase":"2/3","status":"planned"},{"id":"rainbo","name":"RAINBO","nct":"NCT05255653","phase":"2/3","status":"recruiting"},{"id":"rugb","name":"RUGB","nct":"NCT06214572","phase":"2/3","status":"recruiting"},{"id":"nct06712316","name":"Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer","nct":"NCT06712316","phase":"2/3","status":"recruiting"},{"id":"nct05623267","name":"Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT","nct":"NCT05623267","phase":"2/3","status":"recruiting"},{"id":"lung-map","name":"Lung-MAP (SWOG S1400 and S1900)","nct":"NCT02154490","phase":"platform","status":"completed"},{"id":"i-spy-2","name":"I-SPY 2","nct":"NCT01042379","phase":"platform","status":"active"},{"id":"determine-trial","name":"DETERMINE","nct":"NCT05722886","phase":"platform","status":"recruiting"},{"id":"nct05327530","name":"A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)","nct":"NCT05327530","phase":"2","status":"active"},{"id":"nct05061134","name":"A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition","nct":"NCT05061134","phase":"2","status":"active"},{"id":"nct03334617","name":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy","nct":"NCT03334617","phase":"2","status":"active"},{"id":"nct04999969","name":"Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours","nct":"NCT04999969","phase":"2","status":"active"},{"id":"nct04745689","name":"Study of AZD2811 + Durvalumab in ES-SCLC","nct":"NCT04745689","phase":"2","status":"active"},{"id":"nct04941287","name":"Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer","nct":"NCT04941287","phase":"2","status":"active"},{"id":"cupisco","name":"CUPISCO","nct":"NCT03498521","phase":"2","status":"positive"},{"id":"nct04373369","name":"Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer","nct":"NCT04373369","phase":"2"},{"id":"nct03459846","name":"A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)","nct":"NCT03459846","phase":"2","status":"active"},{"id":"nct02519348","name":"A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma","nct":"NCT02519348","phase":"2","status":"active"},{"id":"cave","name":"CAVE mCRC","nct":"NCT04561336","phase":"2","status":"positive"},{"id":"national-lung-matrix-trial","name":"National Lung Matrix Trial","nct":"NCT02664935","phase":"2","status":"completed"},{"id":"trophimmun","name":"TROPHIMMUN","nct":"NCT03135769","phase":"2","status":"positive"},{"id":"keynote-170","name":"KEYNOTE-170","nct":"NCT02576990","phase":"2","status":"positive"},{"id":"mypathway","name":"MyPathway","nct":"NCT02091141","phase":"2","status":"completed"},{"id":"javelin-merkel-200","name":"JAVELIN Merkel 200","nct":"NCT02155647","phase":"2","status":"positive"},{"id":"nct07446387","name":"A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer","nct":"NCT07446387","phase":"2","status":"planned"},{"id":"nct07502014","name":"A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line","nct":"NCT07502014","phase":"2","status":"planned"},{"id":"nct06778031","name":"A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer","nct":"NCT06778031","phase":"2","status":"recruiting"},{"id":"nct05913089","name":"A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer","nct":"NCT05913089","phase":"2","status":"recruiting"},{"id":"nct07255404","name":"A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have N","nct":"NCT07255404","phase":"2","status":"recruiting"},{"id":"nct07297212","name":"A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma","nct":"NCT07297212","phase":"2","status":"recruiting"},{"id":"nct07233850","name":"A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers","nct":"NCT07233850","phase":"2","status":"planned"},{"id":"nct06177925","name":"A Phase II Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC","nct":"NCT06177925","phase":"2","status":"recruiting"},{"id":"nct07241767","name":"A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer","nct":"NCT07241767","phase":"2","status":"recruiting"},{"id":"nct06915142","name":"A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour","nct":"NCT06915142","phase":"2","status":"recruiting"},{"id":"nct07798947","name":"A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC","nct":"NCT07798947","phase":"2","status":"planned"},{"id":"nct06769113","name":"A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy","nct":"NCT06769113","phase":"2","status":"recruiting"},{"id":"nct06769152","name":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors","nct":"NCT06769152","phase":"2","status":"recruiting"},{"id":"nct07729033","name":"A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.","nct":"NCT07729033","phase":"2","status":"planned"},{"id":"nct07679399","name":"A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.","nct":"NCT07679399","phase":"2","status":"recruiting"},{"id":"nct07824882","name":"A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamo","nct":"NCT07824882","phase":"2","status":"planned"},{"id":"nct06728410","name":"A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement","nct":"NCT06728410","phase":"2","status":"recruiting"},{"id":"nct07071714","name":"A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer","nct":"NCT07071714","phase":"2","status":"active"},{"id":"nct07171606","name":"A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients","nct":"NCT07171606","phase":"2","status":"recruiting"},{"id":"nct07444437","name":"A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer","nct":"NCT07444437","phase":"2","status":"recruiting"},{"id":"nct00781612","name":"A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies","nct":"NCT00781612","phase":"2","status":"active"},{"id":"nct07135544","name":"A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer","nct":"NCT07135544","phase":"2","status":"recruiting"},{"id":"nct06096779","name":"A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirr","nct":"NCT06096779","phase":"2","status":"active"},{"id":"nct05645692","name":"A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer","nct":"NCT05645692","phase":"2","status":"active"},{"id":"nct04931342","name":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","nct":"NCT04931342","phase":"2","status":"active"},{"id":"nct05009069","name":"A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer","nct":"NCT05009069","phase":"2","status":"active"},{"id":"nct07538271","name":"A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer","nct":"NCT07538271","phase":"2","status":"planned"},{"id":"nct07654400","name":"A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer","nct":"NCT07654400","phase":"2","status":"recruiting"},{"id":"nct07492680","name":"A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)","nct":"NCT07492680","phase":"2","status":"recruiting"},{"id":"nct05859217","name":"A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)","nct":"NCT05859217","phase":"2","status":"planned"},{"id":"nct06620848","name":"A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.","nct":"NCT06620848","phase":"2","status":"recruiting"},{"id":"nct05805501","name":"A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cel","nct":"NCT05805501","phase":"2","status":"active"},{"id":"nct06667908","name":"A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)","nct":"NCT06667908","phase":"2","status":"recruiting"},{"id":"nct07459634","name":"A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC","nct":"NCT07459634","phase":"2","status":"recruiting"},{"id":"nct04302025","name":"A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)","nct":"NCT04302025","phase":"2","status":"recruiting"},{"id":"nct05844150","name":"A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC","nct":"NCT05844150","phase":"2","status":"active"},{"id":"nct05879055","name":"A Study of PM8002 in Combination With Chemotherapy in Patients With NEN","nct":"NCT05879055","phase":"2","status":"active"},{"id":"nct05879068","name":"A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC","nct":"NCT05879068","phase":"2","status":"active"},{"id":"nct07229729","name":"A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer","nct":"NCT07229729","phase":"2","status":"recruiting"},{"id":"nct06971614","name":"A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC","nct":"NCT06971614","phase":"2","status":"recruiting"},{"id":"nct05968326","name":"A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC","nct":"NCT05968326","phase":"2","status":"active"},{"id":"nct07680764","name":"A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pu","nct":"NCT07680764","phase":"2","status":"recruiting"},{"id":"nct07155174","name":"A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus St","nct":"NCT07155174","phase":"2","status":"recruiting"},{"id":"nct05941897","name":"A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy","nct":"NCT05941897","phase":"2","status":"active"},{"id":"nct06606847","name":"A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small ","nct":"NCT06606847","phase":"2","status":"active"},{"id":"nct06008093","name":"A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS","nct":"NCT06008093","phase":"2","status":"active"},{"id":"nct07235293","name":"A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.","nct":"NCT07235293","phase":"2","status":"recruiting"},{"id":"nct07110571","name":"A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer","nct":"NCT07110571","phase":"2","status":"recruiting"},{"id":"nct07028281","name":"A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors","nct":"NCT07028281","phase":"2","status":"recruiting"},{"id":"nct07268040","name":"A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors","nct":"NCT07268040","phase":"2","status":"recruiting"},{"id":"nct06040099","name":"A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepat","nct":"NCT06040099","phase":"2","status":"active"},{"id":"nct06531278","name":"Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cance","nct":"NCT06531278","phase":"2","status":"recruiting"},{"id":"nct06475209","name":"Adebrelimab + Apatinib in SCLC Maintenance Therapy","nct":"NCT06475209","phase":"2","status":"recruiting"},{"id":"nct06584227","name":"Adebrelimab and Chidamide for Pancreatic Cancer","nct":"NCT06584227","phase":"2","status":"recruiting"},{"id":"nct06916975","name":"Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer","nct":"NCT06916975","phase":"2","status":"planned"},{"id":"nct06177522","name":"Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer","nct":"NCT06177522","phase":"2","status":"planned"},{"id":"nct07230301","name":"Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions","nct":"NCT07230301","phase":"2","status":"planned"},{"id":"nct07561775","name":"Adebrelimab Plus S-1 for Resected Cholangiocarcinoma","nct":"NCT07561775","phase":"2","status":"planned"},{"id":"nct07780838","name":"Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma","nct":"NCT07780838","phase":"2","status":"recruiting"},{"id":"nct07569679","name":"Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer","nct":"NCT07569679","phase":"2","status":"recruiting"},{"id":"nct07061210","name":"An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer","nct":"NCT07061210","phase":"2","status":"planned"},{"id":"nct07668453","name":"An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies","nct":"NCT07668453","phase":"2","status":"recruiting"},{"id":"nct04434040","name":"Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)","nct":"NCT04434040","phase":"2","status":"recruiting"},{"id":"nct06690840","name":"Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients","nct":"NCT06690840","phase":"2","status":"recruiting"},{"id":"nct06663098","name":"Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).","nct":"NCT06663098","phase":"2","status":"recruiting"},{"id":"barbican","name":"BARBICAN","nct":"NCT05498896","phase":"2","status":"active"},{"id":"nct07383285","name":"CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal C","nct":"NCT07383285","phase":"2","status":"planned"},{"id":"nct06280508","name":"Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer","nct":"NCT06280508","phase":"2","status":"recruiting"},{"id":"nct06037655","name":"Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC","nct":"NCT06037655","phase":"2","status":"planned"},{"id":"nct06992336","name":"Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy","nct":"NCT06992336","phase":"2","status":"recruiting"},{"id":"nct07005583","name":"Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent","nct":"NCT07005583","phase":"2","status":"planned"},{"id":"nct07827053","name":"Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer","nct":"NCT07827053","phase":"2","status":"planned"},{"id":"nct07548177","name":"Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma","nct":"NCT07548177","phase":"2","status":"recruiting"},{"id":"nct03937830","name":"Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma","nct":"NCT03937830","phase":"2","status":"active"},{"id":"nct06502080","name":"Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC)","nct":"NCT06502080","phase":"2","status":"planned"},{"id":"nct06953089","name":"DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors","nct":"NCT06953089","phase":"2","status":"recruiting"},{"id":"debate","name":"DEBATE","nct":"NCT04308174","phase":"2","status":"active"},{"id":"diamond","name":"DIAMOND","nct":"NCT06954480","phase":"2","status":"recruiting"},{"id":"nct03482102","name":"Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer","nct":"NCT03482102","phase":"2","status":"active"},{"id":"nct04499053","name":"Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer","nct":"NCT04499053","phase":"2","status":"recruiting"},{"id":"nct05451043","name":"Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)","nct":"NCT05451043","phase":"2","status":"recruiting"},{"id":"nct07081633","name":"Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma","nct":"NCT07081633","phase":"2","status":"active"},{"id":"nct05640791","name":"Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer","nct":"NCT05640791","phase":"2","status":"recruiting"},{"id":"nct06490107","name":"Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC","nct":"NCT06490107","phase":"2","status":"active"},{"id":"nct06463665","name":"Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL ","nct":"NCT06463665","phase":"2","status":"recruiting"},{"id":"nct06282445","name":"Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsate","nct":"NCT06282445","phase":"2","status":"recruiting"},{"id":"nct06229067","name":"Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer","nct":"NCT06229067","phase":"2","status":"planned"},{"id":"nct04891198","name":"ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors","nct":"NCT04891198","phase":"2","status":"recruiting"},{"id":"nct07003815","name":"Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer","nct":"NCT07003815","phase":"2","status":"planned"},{"id":"nct06547736","name":"Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer","nct":"NCT06547736","phase":"2","status":"recruiting"},{"id":"nct06591650","name":"Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer","nct":"NCT06591650","phase":"2","status":"recruiting"},{"id":"nct07599995","name":"Gemcitabine-Cisplatin Plus Envafolimab in Resectable Biliary Tract Malignancies","nct":"NCT07599995","phase":"2","status":"planned"},{"id":"nct06389500","name":"HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer","nct":"NCT06389500","phase":"2","status":"planned"},{"id":"nct07169552","name":"HC010 in First-line PD-L1 Positive Advanced NSCLC Patients","nct":"NCT07169552","phase":"2","status":"recruiting"},{"id":"nct07131514","name":"HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer","nct":"NCT07131514","phase":"2","status":"recruiting"},{"id":"nct06107374","name":"Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG","nct":"NCT06107374","phase":"2","status":"recruiting"},{"id":"nct04238637","name":"Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)","nct":"NCT04238637","phase":"2","status":"active"},{"id":"nct07718490","name":"Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer","nct":"NCT07718490","phase":"2","status":"recruiting"},{"id":"nct04273061","name":"Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity","nct":"NCT04273061","phase":"2","status":"recruiting"},{"id":"nct07447570","name":"Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC","nct":"NCT07447570","phase":"2","status":"recruiting"},{"id":"nct05742607","name":"IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)","nct":"NCT05742607","phase":"2","status":"recruiting"},{"id":"nct03667170","name":"KN035 for dMMR/MSI-H Advanced Solid Tumors","nct":"NCT03667170","phase":"2","status":"recruiting"},{"id":"nct06419179","name":"Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extens","nct":"NCT06419179","phase":"2","status":"recruiting"},{"id":"nct05903092","name":"MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer","nct":"NCT05903092","phase":"2","status":"recruiting"},{"id":"nct07036380","name":"MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma","nct":"NCT07036380","phase":"2","status":"recruiting"},{"id":"nct04910386","name":"Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers","nct":"NCT04910386","phase":"2","status":"planned"},{"id":"nct06610734","name":"Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Ext","nct":"NCT06610734","phase":"2","status":"recruiting"},{"id":"nct05061550","name":"Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer","nct":"NCT05061550","phase":"2","status":"recruiting"},{"id":"nct06342037","name":"NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial","nct":"NCT06342037","phase":"2","status":"recruiting"},{"id":"nct05222971","name":"Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy","nct":"NCT05222971","phase":"2","status":"recruiting"},{"id":"nct05969847","name":"Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer","nct":"NCT05969847","phase":"2","status":"planned"},{"id":"nct06530823","name":"Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma","nct":"NCT06530823","phase":"2","status":"planned"},{"id":"nct05671822","name":"Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer","nct":"NCT05671822","phase":"2","status":"recruiting"},{"id":"nct04379596","name":"Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)","nct":"NCT04379596","phase":"2","status":"active"},{"id":"nct07413601","name":"Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Secon","nct":"NCT07413601","phase":"2","status":"planned"},{"id":"nct03944772","name":"Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)","nct":"NCT03944772","phase":"2","status":"active"},{"id":"nct07175220","name":"Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects","nct":"NCT07175220","phase":"2","status":"recruiting"},{"id":"nct06708858","name":"Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer","nct":"NCT06708858","phase":"2","status":"recruiting"},{"id":"nct06771609","name":"Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy fo","nct":"NCT06771609","phase":"2","status":"recruiting"},{"id":"nct07670273","name":"Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer","nct":"NCT07670273","phase":"2","status":"recruiting"},{"id":"nct07704177","name":"Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer","nct":"NCT07704177","phase":"2","status":"recruiting"},{"id":"nct05280314","name":"Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors","nct":"NCT05280314","phase":"2","status":"recruiting"},{"id":"phoenix","name":"PHOENIX DDR/Anti-PD-L1","nct":"NCT03740893","phase":"2","status":"recruiting"},{"id":"nct07416058","name":"PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC","nct":"NCT07416058","phase":"2","status":"planned"},{"id":"nct07133750","name":"PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer","nct":"NCT07133750","phase":"2","status":"recruiting"},{"id":"nct05845450","name":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","nct":"NCT05845450","phase":"2","status":"recruiting"},{"id":"nct06786026","name":"QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC","nct":"NCT06786026","phase":"2","status":"recruiting"},{"id":"nct06750861","name":"QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC","nct":"NCT06750861","phase":"2","status":"planned"},{"id":"nct06951997","name":"QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer","nct":"NCT06951997","phase":"2","status":"recruiting"},{"id":"nct07110064","name":"QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer","nct":"NCT07110064","phase":"2","status":"recruiting"},{"id":"nct07509515","name":"QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC.","nct":"NCT07509515","phase":"2","status":"planned"},{"id":"nct03228667","name":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","nct":"NCT03228667","phase":"2","status":"active"},{"id":"nct07116577","name":"Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC","nct":"NCT07116577","phase":"2","status":"planned"},{"id":"nct05632809","name":"REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)","nct":"NCT05632809","phase":"2","status":"recruiting"},{"id":"nct05582538","name":"Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel","nct":"NCT05582538","phase":"2","status":"recruiting"},{"id":"nct07752550","name":"Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer","nct":"NCT07752550","phase":"2","status":"planned"},{"id":"nct07773363","name":"Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic Cancer","nct":"NCT07773363","phase":"2","status":"planned"},{"id":"nct05076682","name":"Reverse Triple Negative Immune Resistant Breast Cancer","nct":"NCT05076682","phase":"2","status":"recruiting"},{"id":"nct07150247","name":"Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer","nct":"NCT07150247","phase":"2","status":"recruiting"},{"id":"nct07102901","name":"Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma","nct":"NCT07102901","phase":"2","status":"recruiting"},{"id":"nct05117242","name":"Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer","nct":"NCT05117242","phase":"2","status":"withdrawn"},{"id":"nct06841055","name":"Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Che","nct":"NCT06841055","phase":"2","status":"recruiting"},{"id":"nct06274879","name":"Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer","nct":"NCT06274879","phase":"2","status":"recruiting"},{"id":"nct05374603","name":"Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC","nct":"NCT05374603","phase":"2","status":"active"},{"id":"nct06679673","name":"SHR-1701 Combined with SHR2554 and BP102 for MCRC","nct":"NCT06679673","phase":"2","status":"planned"},{"id":"nct05300269","name":"SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer","nct":"NCT05300269","phase":"2","status":"recruiting"},{"id":"nct06465563","name":"SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer","nct":"NCT06465563","phase":"2","status":"active"},{"id":"nct06819319","name":"SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer","nct":"NCT06819319","phase":"2","status":"planned"},{"id":"nct06680739","name":"Single cEll pRofiling PErsistaNce To ImmuNothErapy","nct":"NCT06680739","phase":"2","status":"recruiting"},{"id":"nct06165900","name":"Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC","nct":"NCT06165900","phase":"2","status":"recruiting"},{"id":"nct06599775","name":"Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer","nct":"NCT06599775","phase":"2","status":"planned"},{"id":"nct03775486","name":"Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)","nct":"NCT03775486","phase":"2","status":"active"},{"id":"nct05112991","name":"Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer","nct":"NCT05112991","phase":"2","status":"recruiting"},{"id":"nct05498155","name":"Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer","nct":"NCT05498155","phase":"2","status":"active"},{"id":"nct05733598","name":"Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC","nct":"NCT05733598","phase":"2","status":"recruiting"},{"id":"nct03547973","name":"Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread","nct":"NCT03547973","phase":"2","status":"active"},{"id":"nct07339059","name":"Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer","nct":"NCT07339059","phase":"2","status":"recruiting"},{"id":"nct06247956","name":"Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer","nct":"NCT06247956","phase":"2","status":"active"},{"id":"nct05925530","name":"Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D,","nct":"NCT05925530","phase":"2","status":"active"},{"id":"nct07322341","name":"SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer","nct":"NCT07322341","phase":"2","status":"recruiting"},{"id":"nct04919382","name":"Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer","nct":"NCT04919382","phase":"2","status":"recruiting"},{"id":"nct03606967","name":"Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer","nct":"NCT03606967","phase":"2","status":"recruiting"},{"id":"nct07704645","name":"The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer","nct":"NCT07704645","phase":"2","status":"planned"},{"id":"nct06266832","name":"The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra","nct":"NCT06266832","phase":"2","status":"recruiting"},{"id":"nct05422690","name":"The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer","nct":"NCT05422690","phase":"2","status":"recruiting"},{"id":"nct07109167","name":"The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors","nct":"NCT07109167","phase":"2","status":"planned"},{"id":"nct07146230","name":"The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2","nct":"NCT07146230","phase":"2","status":"planned"},{"id":"nct05063565","name":"TheraSphere With Durvalumab and Tremelimumab for HCC","nct":"NCT05063565","phase":"2","status":"active"},{"id":"nct04589845","name":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study","nct":"NCT04589845","phase":"2","status":"active"},{"id":"nct07503639","name":"Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer","nct":"NCT07503639","phase":"2","status":"planned"},{"id":"nct04644289","name":"WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC","nct":"NCT04644289","phase":"2","status":"recruiting"},{"id":"nct03742102","name":"A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer","nct":"NCT03742102","phase":"1/2","status":"active"},{"id":"nct03260023","name":"Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers","nct":"NCT03260023","phase":"1/2","status":"active"},{"id":"nct03837899","name":"Durvalumab and Tremelimumab for Pediatric Malignancies","nct":"NCT03837899","phase":"1/2","status":"active"},{"id":"nct02671435","name":"A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors","nct":"NCT02671435","phase":"1/2","status":"active"},{"id":"nct04068610","name":"COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC","nct":"NCT04068610","phase":"1/2","status":"active"},{"id":"nct07227597","name":"A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","nct":"NCT07227597","phase":"1/2","status":"recruiting"},{"id":"nct04370587","name":"A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Adva","nct":"NCT04370587","phase":"1/2","status":"recruiting"},{"id":"nct06840002","name":"A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer","nct":"NCT06840002","phase":"1/2","status":"recruiting"},{"id":"nct06827236","name":"A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer","nct":"NCT06827236","phase":"1/2","status":"recruiting"},{"id":"nct06892548","name":"A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer","nct":"NCT06892548","phase":"1/2","status":"recruiting"},{"id":"nct07079631","name":"A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT3","nct":"NCT07079631","phase":"1/2","status":"recruiting"},{"id":"nct07070232","name":"A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors","nct":"NCT07070232","phase":"1/2","status":"recruiting"},{"id":"nct07111520","name":"A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced ","nct":"NCT07111520","phase":"1/2","status":"recruiting"},{"id":"nct07147348","name":"A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors","nct":"NCT07147348","phase":"1/2","status":"recruiting"},{"id":"nct07736612","name":"A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer","nct":"NCT07736612","phase":"1/2","status":"planned"},{"id":"nct07160725","name":"A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors","nct":"NCT07160725","phase":"1/2","status":"recruiting"},{"id":"nct04538742","name":"A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer","nct":"NCT04538742","phase":"1/2","status":"active"},{"id":"nct06474455","name":"A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors","nct":"NCT06474455","phase":"1/2","status":"recruiting"},{"id":"nct07269158","name":"A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer","nct":"NCT07269158","phase":"1/2","status":"planned"},{"id":"nct04524871","name":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Li","nct":"NCT04524871","phase":"1/2","status":"active"},{"id":"nct03424005","name":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","nct":"NCT03424005","phase":"1/2","status":"recruiting"},{"id":"nct05417321","name":"A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors","nct":"NCT05417321","phase":"1/2","status":"recruiting"},{"id":"nct07280377","name":"A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab","nct":"NCT07280377","phase":"1/2","status":"active"},{"id":"nct04471727","name":"A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)","nct":"NCT04471727","phase":"1/2","status":"active"},{"id":"nct05142696","name":"A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab","nct":"NCT05142696","phase":"1/2","status":"active"},{"id":"nct04895709","name":"A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors","nct":"NCT04895709","phase":"1/2","status":"recruiting"},{"id":"nct04440735","name":"A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors","nct":"NCT04440735","phase":"1/2","status":"active"},{"id":"nct06385678","name":"A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","nct":"NCT06385678","phase":"1/2","status":"active"},{"id":"nct06362252","name":"A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-","nct":"NCT06362252","phase":"1/2","status":"recruiting"},{"id":"nct07174583","name":"A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer","nct":"NCT07174583","phase":"1/2","status":"recruiting"},{"id":"nct05652686","name":"A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)","nct":"NCT05652686","phase":"1/2","status":"recruiting"},{"id":"nct05918133","name":"A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC","nct":"NCT05918133","phase":"1/2","status":"active"},{"id":"nct06754930","name":"A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC","nct":"NCT06754930","phase":"1/2","status":"recruiting"},{"id":"nct06703177","name":"A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors","nct":"NCT06703177","phase":"1/2","status":"recruiting"},{"id":"nct07229586","name":"A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors","nct":"NCT07229586","phase":"1/2","status":"recruiting"},{"id":"nct06589778","name":"A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","nct":"NCT06589778","phase":"1/2","status":"recruiting"},{"id":"nct05440708","name":"A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma","nct":"NCT05440708","phase":"1/2","status":"recruiting"},{"id":"nct07407933","name":"A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors","nct":"NCT07407933","phase":"1/2","status":"recruiting"},{"id":"nct05434234","name":"A Study of YL201 in Patients With Advanced Solid Tumors","nct":"NCT05434234","phase":"1/2","status":"recruiting"},{"id":"nct07325136","name":"A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung ","nct":"NCT07325136","phase":"1/2","status":"recruiting"},{"id":"nct06780137","name":"A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensiv","nct":"NCT06780137","phase":"1/2","status":"recruiting"},{"id":"nct07291076","name":"A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unres","nct":"NCT07291076","phase":"1/2","status":"recruiting"},{"id":"nct07293351","name":"A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal ","nct":"NCT07293351","phase":"1/2","status":"recruiting"},{"id":"nct06618287","name":"A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors","nct":"NCT06618287","phase":"1/2","status":"recruiting"},{"id":"nct06508216","name":"A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negat","nct":"NCT06508216","phase":"1/2","status":"recruiting"},{"id":"nct05482568","name":"A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer","nct":"NCT05482568","phase":"1/2","status":"recruiting"},{"id":"nct07059221","name":"A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer","nct":"NCT07059221","phase":"1/2","status":"recruiting"},{"id":"nct06474468","name":"A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer","nct":"NCT06474468","phase":"1/2","status":"recruiting"},{"id":"nct06512051","name":"A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer","nct":"NCT06512051","phase":"1/2","status":"recruiting"},{"id":"nct06639347","name":"A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma","nct":"NCT06639347","phase":"1/2","status":"recruiting"},{"id":"nct06417554","name":"A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors","nct":"NCT06417554","phase":"1/2","status":"recruiting"},{"id":"nct07392541","name":"Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer","nct":"NCT07392541","phase":"1/2","status":"recruiting"},{"id":"nct07293754","name":"An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors","nct":"NCT07293754","phase":"1/2","status":"recruiting"},{"id":"nct03533283","name":"An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","nct":"NCT03533283","phase":"1/2","status":"active"},{"id":"nct07806058","name":"An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors","nct":"NCT07806058","phase":"1/2","status":"planned"},{"id":"nct07371663","name":"An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors","nct":"NCT07371663","phase":"1/2","status":"recruiting"},{"id":"nct05000294","name":"Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types","nct":"NCT05000294","phase":"1/2","status":"recruiting"},{"id":"nct03539822","name":"Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies","nct":"NCT03539822","phase":"1/2","status":"recruiting"},{"id":"nct05927142","name":"Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for The","nct":"NCT05927142","phase":"1/2","status":"recruiting"},{"id":"nct06548412","name":"CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers","nct":"NCT06548412","phase":"1/2","status":"recruiting"},{"id":"nct07707895","name":"DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers","nct":"NCT07707895","phase":"1/2","status":"planned"},{"id":"nct06427239","name":"Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma","nct":"NCT06427239","phase":"1/2","status":"recruiting"},{"id":"nct05438329","name":"First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors","nct":"NCT05438329","phase":"1/2","status":"active"},{"id":"nct07802184","name":"GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC","nct":"NCT07802184","phase":"1/2","status":"planned"},{"id":"nct07636798","name":"Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer","nct":"NCT07636798","phase":"1/2","status":"recruiting"},{"id":"nct07296341","name":"HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors","nct":"NCT07296341","phase":"1/2","status":"recruiting"},{"id":"nct06631079","name":"Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors","nct":"NCT06631079","phase":"1/2","status":"active"},{"id":"nct07073534","name":"Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors","nct":"NCT07073534","phase":"1/2","status":"recruiting"},{"id":"nct06110572","name":"Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation","nct":"NCT06110572","phase":"1/2","status":"recruiting"},{"id":"nct06454448","name":"Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic P","nct":"NCT06454448","phase":"1/2","status":"recruiting"},{"id":"nct05503888","name":"Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer","nct":"NCT05503888","phase":"1/2","status":"planned"},{"id":"nct05024214","name":"Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors","nct":"NCT05024214","phase":"1/2","status":"recruiting"},{"id":"nct05918445","name":"PM8002 in the Treatment of Patients With Advanced Solid Tumors","nct":"NCT05918445","phase":"1/2","status":"recruiting"},{"id":"nct07453394","name":"QLS5132 Combination Therapy in Advanced Solid Tumors","nct":"NCT07453394","phase":"1/2","status":"planned"},{"id":"nct05703971","name":"Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients","nct":"NCT05703971","phase":"1/2","status":"recruiting"},{"id":"nct06373133","name":"SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer","nct":"NCT06373133","phase":"1/2","status":"planned"},{"id":"nct05501665","name":"Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer","nct":"NCT05501665","phase":"1/2","status":"recruiting"},{"id":"nct05267626","name":"Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Ca","nct":"NCT05267626","phase":"1/2","status":"recruiting"},{"id":"nct06222879","name":"Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer","nct":"NCT06222879","phase":"1/2","status":"recruiting"},{"id":"nct07227298","name":"Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers","nct":"NCT07227298","phase":"1/2","status":"recruiting"},{"id":"nct04068194","name":"Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies","nct":"NCT04068194","phase":"1/2","status":"active"},{"id":"nct04781192","name":"The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers","nct":"NCT04781192","phase":"1/2","status":"active"},{"id":"nct04691817","name":"Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based T","nct":"NCT04691817","phase":"1/2","status":"recruiting"},{"id":"nct05187338","name":"Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors","nct":"NCT05187338","phase":"1/2","status":"recruiting"},{"id":"autogene-cevumeran-phase-1","name":"Autogene cevumeran phase 1 in resected pancreatic cancer (Memorial Sloan Kettering)","nct":"NCT04161755","phase":"1","status":"active"},{"id":"ck-301-101","name":"CK-301-101","nct":"NCT03212404","phase":"1","status":"active"},{"id":"abc-12","name":"ABC-12","nct":"ISRCTN11210442","phase":"observational","status":"active"}],"pathways":["antigen-presentation-immunoediting","hepatocellular-carcinoma-signalling","jak-stat","myeloid-suppression-axis","pd1-checkpoint"],"companies":["3d-medicines","3sbio","agilent","alphamab","astrazeneca","biontech","checkpoint-therapeutics","chugai","compass-therapeutics","cstone","genmab","huabo-biopharm","immvira-pharma","insight-molecular-diagnostics","io-biotech","hengrui","lees-pharmaceutical","onc-ai","oncohost","pfizer","qilu-pharmaceutical","roche-genentech","henlius","sino-biopharm","sun-pharma","tracon"],"keyPapers":["paper-imvigor011-nejm-2025","paper-adriatic-nejm-2024","paper-niagara-nejm-2024","paper-keynote-042-tmb-mutations-ann-oncol-2023","paper-keynote-189-407-tmb-jtocrr-2023","paper-sigurjonsdottir-sp142-22c3-tnbc-bcr-2023","paper-ck-301-101-jitc-2023","paper-heymach-aegean-perioperative-durvalumab-nejm-2023","paper-ricciuti-tmb-pd-l1-levels-jama-oncol-2022","paper-asco-biomarkers-metastatic-breast-cancer-guideline-jco-2022","paper-ricciuti-stk11-keap1-kras-immunotherapy-jto-2022","paper-spigel-pacific-five-year-survival-jco-2022","paper-felip-impower010-adjuvant-atezolizumab-lancet-2021","paper-checkmate-649-lancet-2021","paper-patil-gallbladder-immune-microenvironment-aimm-2021","paper-lehmann-tnbc-subtype-multiomics-nat-commun-2021","paper-rugo-pd-l1-assay-comparison-impassion130-jnci-2021","paper-albrecht-pdl1-western-gallbladder-cancers-2021","paper-herbst-impower110-atezolizumab-pd-l1-nejm-2020","paper-imbrave150-nejm-2020","paper-barroso-sousa-tmb-pten-ici-mtnbc-ccr-2020","paper-bareche-tnbc-microenvironment-jnci-2020","paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019","paper-oreilly-durvalumab-tremelimumab-pancreatic-jama-oncol-2019","paper-weinberg-biliary-profiling-jgo-2019","paper-gruosso-tnbc-spatial-immune-microenvironments-jci-2019","paper-binnewies-tumor-immune-microenvironment-natmed-2018","paper-gandara-blood-tmb-atezolizumab-nat-med-2018","paper-neyaz-pdl1-gallbladder-histopathology-2018","paper-keynote-189-nejm-2018","paper-rizvi-targeted-ngs-immunotherapy-determinants-jco-2018","paper-checkmate-227-n-engl-j-med-2018","paper-blueprint-phase-2-pd-l1-assays-jto-2018","paper-ribas-wolchok-checkpoint-blockade-science-2018","paper-kras-nsclc-cancer-discov-2018","paper-rimm-pd-l1-assay-comparison-jama-oncol-2017","paper-checkmate-026-first-line-nivolumab-nejm-2017","paper-pacific-nejm-2017","paper-hirsch-j-thorac-oncol","paper-keynote-010-lancet-2016","paper-keynote-024-nejm-2016","paper-checkmate-017-nejm-2015","paper-checkmate-057-nejm-2015","paper-skoulidis-kras-co-mutation-subsets-cancer-discov-2015","paper-keynote-001-pembrolizumab-nsclc-nejm-2015","paper-rizvi-mutational-landscape-pd1-science-2015","paper-tumeh-pd1-adaptive-immune-resistance-nature-2014","paper-chen-mellman-cancer-immunity-cycle-immunity-2013","paper-feig-cxcl12-fap-cafs-t-cell-exclusion-pnas-2013","paper-pardoll-immune-checkpoint-blockade-nrc-2012","paper-brahmer-anti-pd-l1-phase-1-nejm-2012","paper-schreiber-cancer-immunoediting-science-2011","paper-iwai-pdl1-tumour-escape-pnas-2002"],"hotspots":[],"openQuestions":[{"id":"pdl1-cutpoints","question":"Can PD-L1 scoring be harmonised across antibodies (22C3, SP263, 28-8, SP142) and cut-points (TPS, CPS, IC) so one test serves every drug?","stage":"implementation","actor":"regulator","source":{"label":"KEYNOTE-189, NEJM 2018","url":"https://doi.org/10.1056/NEJMoa1801005"}}],"assays":[{"id":"pdl1-22c3","name":"PD-L1 IHC 22C3 pharmDx","cutoff":"TPS at least 1% or at least 50% (NSCLC); CPS at least 1 (head and neck, oesophageal, gastric); CPS at least 10 (TNBC, gastric first line); CPS at least 1 (cervical)"},{"id":"pdl1-sp142","name":"VENTANA PD-L1 (SP142) Assay","cutoff":"IC at least 5% (urothelial, historic); IC at least 1% (TNBC, indication later withdrawn); TC at least 50% or IC at least 10% (NSCLC)"},{"id":"pdl1-sp263","name":"VENTANA PD-L1 (SP263) Assay","cutoff":"TC at least 1% (durvalumab after chemoradiotherapy, NSCLC; PACIFIC-derived)"},{"id":"pdl1-28-8","name":"PD-L1 IHC 28-8 pharmDx","cutoff":"TC at least 1% (nivolumab plus ipilimumab, first-line NSCLC)"},{"id":"signatera-mrd","name":"Signatera (tumour-informed ctDNA MRD)","cutoff":"Two or more variants detected above the assay threshold defines ctDNA-positive (IMvigor011: adjuvant atezolizumab for ctDNA-positive bladder cancer)"}],"resistance":[{"class":"pd1-blockade","mechanism":"Loss of antigen presentation (B2M, HLA, JAK1/2)","category":"immune-evasion"},{"class":"pd1-blockade","mechanism":"Immune-desert / excluded tumours","category":"immune-evasion"},{"class":"pd1-blockade","mechanism":"Alternative checkpoints (LAG-3, TIM-3, TIGIT)","category":"bypass"},{"class":"pd1-blockade","mechanism":"Immunosuppressive myeloid cells and VEGF","category":"immune-evasion"},{"class":"pd1-blockade","mechanism":"Loss of neoantigens / low TMB","category":"antigen"}],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}